about
Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium bergheiHistidine affinity tags affect MSP1(42) structural stability and immunodominance in mice.Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialProtection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responsesAntibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsPhase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigenIdentification and targeting of tumor escape mechanisms: a new hope for cancer therapy?Danger, death and DNA vaccines.Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.Complement 3d: from molecular adjuvant to target of immune escape mechanisms.Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodiesMSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum.Novel ELISA method as exploratory tool to assess immunity induced by radiated attenuated sporozoites to decipher protective immunity.C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.MFG-E8/Lactadherin Promotes Tumor Growth in an Angiogenesis-Dependent Transgenic Mouse Model of Multistage CarcinogenesisNovel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunityComparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination
P50
Q28749621-C69F0FD8-CCE4-4DEF-91DB-212D7AC3CF6BQ30409373-F50DDC24-9E47-4BE5-9AA9-EEBDB6824C62Q33316023-8F3EE4CA-D302-4657-839C-D3AFCB2D4FAAQ33356029-95F2E012-65B6-4CA2-B629-F8D81C582896Q33380213-DA01BF7D-C6DC-46EA-80F3-0AB5D6AC96BDQ33434412-62F8FBE2-A161-43B4-B45A-103282BEFD31Q33481160-010BE236-F5FF-4302-B8BF-73904F4B4F38Q33996076-66F2DC56-8797-41B7-A709-40DB27E8CA94Q34606356-F16247AA-3D71-4A64-B0E9-27C1CD333E4FQ34703631-2EA2DC67-9739-4321-8E1F-ECD2BC5D43D5Q34705057-6B9F7659-1AC5-468C-962A-51947AC68A44Q34971618-C3B4CB3F-E762-459D-BE09-8B74D82FA375Q35551943-46BDCFBC-9E4D-452B-8F9C-18CBB0C34298Q35738697-FB7DBF29-1C29-4842-A0AE-12CA80CF367EQ36412687-06D4E454-6C96-4AE7-BA93-499794BBD6B9Q36567985-5371A300-57B2-451A-B4AB-10FF79B99AD4Q36639261-BE0D32B4-BC4D-4B03-88F9-459842AECABDQ41172326-1E495470-9F67-4485-A0DE-B351B458E3B5Q42151010-E61FB83E-6E42-4C58-82A6-9ED303CE3122Q47135372-E8DF6816-D42F-490D-8058-A98695448242Q47846079-337E7CB6-4D28-43E8-8133-DFB7E74DACB8Q47917346-0ECF69A4-6A75-4C3C-9B62-12C8C4B2C39EQ48003719-A8CE32B9-0DBC-4609-B112-73E1957ED47EQ58429003-DA56CA21-9419-4DD6-A8D5-33DDAC2F0E73Q64935759-3F961A9D-56BA-4C77-86A9-8202DB0CEA82Q90560580-0731AECB-226B-404A-9499-A8DD17D139F0Q92022239-A895245B-E6BD-4F37-9FED-67015E70BA75
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elke S Bergmann-Leitner
@ast
Elke S Bergmann-Leitner
@en
Elke S Bergmann-Leitner
@es
Elke S Bergmann-Leitner
@nl
Elke S Bergmann-Leitner
@sl
type
label
Elke S Bergmann-Leitner
@ast
Elke S Bergmann-Leitner
@en
Elke S Bergmann-Leitner
@es
Elke S Bergmann-Leitner
@nl
Elke S Bergmann-Leitner
@sl
prefLabel
Elke S Bergmann-Leitner
@ast
Elke S Bergmann-Leitner
@en
Elke S Bergmann-Leitner
@es
Elke S Bergmann-Leitner
@nl
Elke S Bergmann-Leitner
@sl
P106
P21
P31
P496
0000-0002-8571-8956